Passage Bio (PASG) Expected to Announce Earnings on Monday

Passage Bio (NASDAQ:PASG) is expected to release its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect the company to post earnings of ($2.27) per share for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Passage Bio (NASDAQ:PASG) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($2.36) earnings per share for the quarter, beating the consensus estimate of ($2.76) by $0.40. On average, analysts expect Passage Bio to post $-9 EPS for the current fiscal year and $-9 EPS for the next fiscal year.

Passage Bio Stock Down 0.4%

Shares of NASDAQ:PASG opened at $4.47 on Friday. Passage Bio has a 12-month low of $3.29 and a 12-month high of $20.00. The stock has a market cap of $14.35 million, a PE ratio of -0.38 and a beta of 1.42. The business has a 50 day moving average of $5.14 and a 200-day moving average of $7.39.

Insiders Place Their Bets

In related news, major shareholder Lynx1 Capital Management Lp acquired 50,055 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was purchased at an average cost of $4.12 per share, with a total value of $206,226.60. Following the acquisition, the insider directly owned 673,759 shares of the company’s stock, valued at approximately $2,775,887.08. The trade was a 8.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PASG. Renaissance Technologies LLC lifted its position in Passage Bio by 8.2% during the fourth quarter. Renaissance Technologies LLC now owns 109,089 shares of the company’s stock worth $1,287,000 after purchasing an additional 8,300 shares during the period. Yiheng Capital Management L.P. acquired a new stake in Passage Bio during the fourth quarter worth about $405,000. Geode Capital Management LLC increased its holdings in Passage Bio by 15.1% in the 4th quarter. Geode Capital Management LLC now owns 31,397 shares of the company’s stock valued at $371,000 after buying an additional 4,114 shares during the period. Squarepoint Ops LLC bought a new position in Passage Bio in the 3rd quarter valued at about $188,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Passage Bio in the 4th quarter valued at approximately $148,000. Institutional investors and hedge funds own 53.48% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Passage Bio in a report on Wednesday, June 24th. Guggenheim cut Passage Bio from a “buy” rating to a “neutral” rating in a research report on Wednesday, June 10th. TD Cowen downgraded Passage Bio from a “buy” rating to a “hold” rating in a report on Tuesday, April 21st. Oppenheimer dropped their target price on Passage Bio from $30.00 to $15.00 and set an “outperform” rating for the company in a report on Tuesday, April 21st. Finally, Wedbush reissued a “neutral” rating and issued a $8.00 price objective (down from $32.00) on shares of Passage Bio in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.25.

About Passage Bio

Passage Bio is a clinical-stage biotechnology company focused on the development of gene therapies to treat rare, monogenic central nervous system and neuromuscular disorders. The company applies its in-house gene therapy platform to design and engineer adeno-associated virus (AAV)–based vectors that restore or replace defective genes, aiming to deliver durable treatments with a single administration.

The company’s lead programs include PBGM01, an AAV9-based therapy for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), which is conducting a first-in-human study to assess safety and potential therapeutic benefit.